Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Dawn was breaking when the musicians stumbled out of the church after an all-night recording session with Jordi Savall….
Author: admin
-
AI credit concerns playing out differently in investment grade and high yield, Goldman says – Reuters
- AI credit concerns playing out differently in investment grade and high yield, Goldman says Reuters
- Wall Street races to protect itself from AI bubble Rolling Out
- Barclays exec says top five tech firms could need $100 billion in funding next year WKZO
- The AI Industry’s Tangled Finances The Dispatch
- Taking a position: AI debt frenzy gives birth to new CDS markets IFR Asia
Continue Reading
-
Max Whitlock details plans for return, desire to expand skill repertoire
A week after double Olympic artistic gymnastics champion Max Whitlock announced his return to training and dreams of a fifth Olympic Games appearance at LA28, the 32-year-old has detailed his comeback plans in an exclusive interview with…
Continue Reading
-
FDA Okays CAR T-Cell Therapy for Marginal Zone Lymphoma – Medscape
- FDA Okays CAR T-Cell Therapy for Marginal Zone Lymphoma Medscape
- Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Bristol Myers Squibb
- Bristol Myers Squibb wins fifth US approval for CAR T cell therapy Breyanzi European Pharmaceutical Review
- FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma Oncology Nursing News
- FDA Approves CAR-T Therapy for Marginal Zone Lymphoma Oncology News Central
Continue Reading
-
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year’s meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi’s innovative portfolio including data from efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. These presentations underscore Sobi’s mission to deliver life-changing therapies for patients with rare and severe blood disorders.
“We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. These findings matter because they address key drivers of morbidity which affect daytoday functioning and quality of life. The ASH meeting also offers an opportunity to discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
Summary of full Sobi data to be presented at ASH 2025:
Efanesoctocog alfa
Clinical outcomes up to four years of once-weekly Efanesoctocog Alfa Prophylaxis in previously treated adults, adolescents, and children with severe Haemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study.
Oral Presentation
Session Name: 322. Haemophilia A and B: Clinical and epidemiological: Innovations shaping the future of Haemophilia care
Date: 7 December 2025
Time: 12:00 PM – 1:30 PM ET
Presentation Time: 1:00 PM – 1:15 PM ET
Room: OCCC – W304EFGH
Publication Number: 539
Understanding unmet needs for people with Haemophilia A receiving factor and non-factor treatments.
Poster Presentation
Session Name: Poster Session I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Publication Number: 2679
Real-world experience of Efanesoctocog Alfa in Haemophilia A patients in the US: A retrospective analysis.
Poster Presentation
Session Name: Poster Session I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Publication Number: 1286
Patient characteristics, treatment patterns, and bleeding in people with Haemophilia A without inhibitors initiating Efanesoctocog alfa in the US: An administrative claims analysis.
Poster Presentation
Session Name: Poster Session I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Publication Number: 1290
Quality of life and functional improvements with Efanesoctocog alfa in patients with moderate to severe Haemophilia A: A real-world survey.
Poster Presentation
Session name: Poster Session III
Date: 8 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Publication Number: 4846
Pegcetacoplan
Consistent benefits of Pegcetacoplan treatment in PNH patients with and without a history of Aplastic Anaemia in real world: Analysis of the ongoing COMPLETE Phase 4 observational study.
Poster Presentation
Session Name: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Early results from the ongoing Pegcetacoplan Silo of the International Paroxysmal Nocturnal Haemoglobinuria Interest Group Registry.
Poster Presentation
Session Name: 508. Bone Marrow Failure: Acquired: Poster II
Date: 7 December 2025
Time: 6:00:00 PM – 6:00:00 PM ET
Location: OCCC – West Halls B3-B4
Real-world clinical characteristics and treatment outcomes in PNH patients prescribed Pegcetacoplan: Insights of complement inhibitor-experienced and -naïve patients across Europe, the United States and Canada.
Poster Presentation
Session Name: 508. Bone Marrow Failure: Acquired: Poster III
Date: 8 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Pegcetacoplan – Publication Only Abstracts
Real-world effectiveness of Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria: A systematic review of clinical and patient-reported outcomes.
Publication only – published online on 3 November 2025, at 9:00 AM ET
Low risk for Meningococcal and encapsulated bacteria infections with systemically administered Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria and C3 Glomerulopathies.
Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria.
Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report.
User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria.
Avatrombopag
Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from Eltrombopag or Romiplostim to Avatrombopag in the United States: Results from the real-AVA 3.5 study.
Poster Presentation
Session Name: 905. Outcomes research: Non-malignant conditions excluding Hemoglobinopathies: Poster I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Real-world safety and efficacy of Avatrombopag in adults with Immune Thrombocytopenia: A systematic review and meta-analysis.
Global Abstract
Session Name: 311. Disorders of platelet number or function: Clinical and epidemiological: Poster I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Patient-reported outcomes of Avatrombopag for Chronic Immune Thrombocytopenia: Interim analysis of the Phase 4 ADOPT Study.
Poster Presentation
Session Name: 905. Outcomes research: Non-malignant conditions excluding Hemoglobinopathies: Poster III
Date: 8 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Emapalumab
Use of Emapalumab is associated with rapid and sustained benefits in pHLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109.
Poster Presentation
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster II
Date: 7 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09.
Poster Presentation
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date: 8 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Pacritinib
Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anaemia at initiation of Pacritinib treatment.
Oral Presentation
Session Name: 908. Outcomes Research: Myeloid
Malignancies: Real-World Experiences
Session date: 7 December 2025
Session time: 4:30 PM – 6:00 PM ET
Presentation time: 5:30 PM – 5:45 PM
Room: OCCC – W414CD
Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies.
Poster Presentation
Session Name: 634. Myeloproliferative Syndromes: Clinical and epidemiological: Poster I
Date: 6 December 2025
Time: 5:30 PM – 7:30 PM ET
Room: OCCC – West Halls B3-B4
Real-world treatment patterns and clinical outcomes in patients with Myelofibrosis treated with Pacritinib (PAC): Results from the MY-PAC Study.
Poster Presentation
Session Name: 908. Outcomes research: Myeloid Malignancies: Poster II
Date: 7 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
PROSPERA (ABNL-MARRO 002): A randomised Phase 2 study of Pacritinib vs. Hydroxyurea in patients with Advanced Proliferative Chronic Myelomonocytic Leukaemia (CMML)
Poster Presentation
Session Name: 637. Myelodysplastic Syndromes: Clinical and epidemiological: Poster II
Date: 7 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Treatment patterns and outcomes in patients with myelofibrosis treated with Pacritinib following a switch from Ruxolitinib: The MY-PAC Study.
Session Name: 634. Myeloproliferative Syndromes: Clinical and epidemiological: Poster III
Date: 8 December 2025
Time: 6:00 PM – 8:00 PM ET
Room: OCCC – West Halls B3-B4
Incidence, prevalence, and clinical outcomes of Myelofibrosis with and without Cytopenia in the United States.
About ALTUVOCT ® (efanesoctocog alfa)
ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity.
About the Sobi and Sanofi Collaboration
Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.About Aspaveli®/Empaveli® (pegcetacoplan)
Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally.About the Sobi and Apellis Collaboration
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.
About Doptelet® (avatrombopag)
Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients.
About Gamifant® (emapalumab-lzsg)
Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still’s disease.About Vonjo® (pacritinib)
Vonjo (pacritinib) is a kinase inhibitor indicated in the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome.Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Continue Reading
-
Apple, Google send new round of cyber threat notifications to users around world – Reuters
- Apple, Google send new round of cyber threat notifications to users around world Reuters
- Apple Warns Users in 84 Countries of New Cyber Threat Activity TradingView
- Apple Issues Huge State-Backed Hacking Warning to Global Users TipRanks
- Apple sent new round of cyber threat notifications to users in 84 countries By Reuters Investing.com
- Apple (AAPL) Stock: Company Issues Cyber Threat Warnings to Users in 84 Countries Blockonomi
Continue Reading
-
X hit with $140 million EU fine for breaching content rules, TikTok settles – Reuters
- X hit with $140 million EU fine for breaching content rules, TikTok settles Reuters
- Elon Musk’s X Hit With $140 Million Fine in Europe The New York Times
- Elon Musk’s X fined €120m by EU in first clash under new digital laws The Guardian
- Digital Services Act: Commission fines X for violating transparency obligations European Interest
- EU may consolidate crypto regulations, IMF warns of stablecoin risk: Global Express TradingView
Continue Reading
-
Catherine’s message of togetherness at carol concert
Sean CoughlanRoyal correspondent, Westminster Abbey
ReutersCatherine arrives at Westminster Abbey ahead of the carol service The Princess of Wales is hosting her annual Christmas carol concert at Westminster Abbey, with guests including royals,…
Continue Reading
-
Katy Perry joins boyfriend Justin Trudeau for diplomatic mission
Justin Trudeau and Katy Perry first sparked romance rumours in July 2025 Justin Trudeau and Katy Perry just took their relationship to the diplomatic level.
During their trip to Japan, the new couple joined former…
Continue Reading
-
Kirkland Advises 26North on Acquisition of Controlling Interest in Residential Kitchen | News
Kirkland & Ellis advised 26North Partners on an agreement to purchase a controlling interest in The Middleby Corporation’s (NYSE: MIDD) Residential Kitchen business at a valuation of $885 million, creating a leading platform in premium cooking, refrigeration and outdoor living. Residential Kitchen’s portfolio includes iconic, category-defining brands across premium cooking, refrigeration and outdoor living in the U.S. and Europe, such as Viking, AGA, Rangemaster, La Cornue, Lynx, U-Line, Kamado Joe and Masterbuilt.
Read the transaction press release
The Kirkland team included corporate lawyers Eduardo Leal, Peter Martelli and Aseda Ghartey-Tagoe; debt finance lawyers Doug Tedeschi, Andrew Hurley and Judson Oswald; and tax lawyers Vivek Ratnam and Mike Beinus.
Continue Reading